Ampicillin/sulbactam versus cefazolin or cefoxitin in the treatment of skin and skin-structure infections of bacterial etiology

J. C. Chan

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

This randomized, double-blind study compared 1 g of ampicillin plus 0.5 g of sulbactam with 0.5 g of cefazolin in the treatment of cellulitis and with 1 g of cefoxitin in other skin and skin-structure infections. Study drugs were administered intravenously every 6 hours to 58 hospitalized patients. Each indication was evaluated separately. In cellulitis, ampicillin/sulbactam and cefazolin produced clinical cure or improvement in 100% and 91.7% of patients, respectively; duration of hospitalization was 7.7 and 7.2 days. In other skin and skin structure infections, results for ampicillin/sulbactam and cefoxitin, respectively, were clinical cure or improvement, 80% and 64.7%; treatment failures, 0% and 11.8%; bacterial eradication, 40% and 53%; and duration of hospitalization, 7.7 and 9.4 days. No unusual or unexpected adverse experiences related to any study drug occurred. One patient treated with ampicillin/sulbactam died of a pulmonary embolism, and 1 patient treated with cefoxitin was discontinued from the study following amputation of an infected foot. These events were not considered drug-related. The treatment groups showed no statistically significant differences in efficacy or safety.

Original languageEnglish
Pages (from-to)139-146
Number of pages8
JournalAdvances in Therapy
Volume12
Issue number2
StatePublished - May 16 1995
Externally publishedYes

Fingerprint

Bacterial Structures
Cefoxitin
Cefazolin
Bacterial Infections
Skin
Cellulitis
Hospitalization
Pharmaceutical Preparations
Sulbactam
Therapeutics
Ampicillin
Infection
Treatment Failure
Pulmonary Embolism
Amputation
Double-Blind Method
Foot
Safety
sultamicillin

Keywords

  • ampicillin/sulbactam
  • cefazolin
  • cefoxitin
  • cellulitis
  • skin infections

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ampicillin/sulbactam versus cefazolin or cefoxitin in the treatment of skin and skin-structure infections of bacterial etiology. / Chan, J. C.

In: Advances in Therapy, Vol. 12, No. 2, 16.05.1995, p. 139-146.

Research output: Contribution to journalArticle

@article{e5e600a8f90849b68e76adf399b2394b,
title = "Ampicillin/sulbactam versus cefazolin or cefoxitin in the treatment of skin and skin-structure infections of bacterial etiology",
abstract = "This randomized, double-blind study compared 1 g of ampicillin plus 0.5 g of sulbactam with 0.5 g of cefazolin in the treatment of cellulitis and with 1 g of cefoxitin in other skin and skin-structure infections. Study drugs were administered intravenously every 6 hours to 58 hospitalized patients. Each indication was evaluated separately. In cellulitis, ampicillin/sulbactam and cefazolin produced clinical cure or improvement in 100{\%} and 91.7{\%} of patients, respectively; duration of hospitalization was 7.7 and 7.2 days. In other skin and skin structure infections, results for ampicillin/sulbactam and cefoxitin, respectively, were clinical cure or improvement, 80{\%} and 64.7{\%}; treatment failures, 0{\%} and 11.8{\%}; bacterial eradication, 40{\%} and 53{\%}; and duration of hospitalization, 7.7 and 9.4 days. No unusual or unexpected adverse experiences related to any study drug occurred. One patient treated with ampicillin/sulbactam died of a pulmonary embolism, and 1 patient treated with cefoxitin was discontinued from the study following amputation of an infected foot. These events were not considered drug-related. The treatment groups showed no statistically significant differences in efficacy or safety.",
keywords = "ampicillin/sulbactam, cefazolin, cefoxitin, cellulitis, skin infections",
author = "Chan, {J. C.}",
year = "1995",
month = "5",
day = "16",
language = "English",
volume = "12",
pages = "139--146",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",
number = "2",

}

TY - JOUR

T1 - Ampicillin/sulbactam versus cefazolin or cefoxitin in the treatment of skin and skin-structure infections of bacterial etiology

AU - Chan, J. C.

PY - 1995/5/16

Y1 - 1995/5/16

N2 - This randomized, double-blind study compared 1 g of ampicillin plus 0.5 g of sulbactam with 0.5 g of cefazolin in the treatment of cellulitis and with 1 g of cefoxitin in other skin and skin-structure infections. Study drugs were administered intravenously every 6 hours to 58 hospitalized patients. Each indication was evaluated separately. In cellulitis, ampicillin/sulbactam and cefazolin produced clinical cure or improvement in 100% and 91.7% of patients, respectively; duration of hospitalization was 7.7 and 7.2 days. In other skin and skin structure infections, results for ampicillin/sulbactam and cefoxitin, respectively, were clinical cure or improvement, 80% and 64.7%; treatment failures, 0% and 11.8%; bacterial eradication, 40% and 53%; and duration of hospitalization, 7.7 and 9.4 days. No unusual or unexpected adverse experiences related to any study drug occurred. One patient treated with ampicillin/sulbactam died of a pulmonary embolism, and 1 patient treated with cefoxitin was discontinued from the study following amputation of an infected foot. These events were not considered drug-related. The treatment groups showed no statistically significant differences in efficacy or safety.

AB - This randomized, double-blind study compared 1 g of ampicillin plus 0.5 g of sulbactam with 0.5 g of cefazolin in the treatment of cellulitis and with 1 g of cefoxitin in other skin and skin-structure infections. Study drugs were administered intravenously every 6 hours to 58 hospitalized patients. Each indication was evaluated separately. In cellulitis, ampicillin/sulbactam and cefazolin produced clinical cure or improvement in 100% and 91.7% of patients, respectively; duration of hospitalization was 7.7 and 7.2 days. In other skin and skin structure infections, results for ampicillin/sulbactam and cefoxitin, respectively, were clinical cure or improvement, 80% and 64.7%; treatment failures, 0% and 11.8%; bacterial eradication, 40% and 53%; and duration of hospitalization, 7.7 and 9.4 days. No unusual or unexpected adverse experiences related to any study drug occurred. One patient treated with ampicillin/sulbactam died of a pulmonary embolism, and 1 patient treated with cefoxitin was discontinued from the study following amputation of an infected foot. These events were not considered drug-related. The treatment groups showed no statistically significant differences in efficacy or safety.

KW - ampicillin/sulbactam

KW - cefazolin

KW - cefoxitin

KW - cellulitis

KW - skin infections

UR - http://www.scopus.com/inward/record.url?scp=0029006546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029006546&partnerID=8YFLogxK

M3 - Article

C2 - 10150324

AN - SCOPUS:0029006546

VL - 12

SP - 139

EP - 146

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 2

ER -